{
  "_metadata": {
    "version": "2.0",
    "ticker": "ARGX",
    "asset_id": "empasiprubart",
    "internal_id": "ARGX-117",
    "data_source": "argenx 2026 JPM Corporate Presentation",
    "extraction_date": "2026-02-04",
    "last_updated": "2026-02-04"
  },
  "asset": {
    "name": "empasiprubart",
    "internal_id": "ARGX-117",
    "modality": "C2 sweeping antibody",
    "route": "IV/SC",
    "description": "Potent C2 sweeping antibody for complement-mediated diseases"
  },
  "target": {
    "primary_target": "Complement C2",
    "target_class": "Complement pathway component",
    "biology": {
      "function": "C2 is a component of the classical and lectin complement pathways. C2 cleavage is required for formation of C3 convertase, which amplifies complement activation",
      "mechanism": "Empasiprubart is a 'sweeping' antibody that binds C2 and accelerates its clearance from circulation, leading to sustained complement inhibition",
      "pathway_position": "Upstream inhibition (C2) vs downstream inhibitors (C5)",
      "differentiation": "Sweeping mechanism provides sustained C2 depletion"
    },
    "genetic_validation": {
      "rationale": "Complement activation implicated in multiple autoimmune and inflammatory diseases; C2 deficiency is the most common complement deficiency in humans, generally well-tolerated"
    },
    "why_good_target": {
      "rationale": [
        "Complement activation drives pathology in many neurological and autoimmune diseases",
        "Upstream inhibition may provide broader effect than C5 inhibitors",
        "C2 sweeping provides sustained complement suppression",
        "Differentiated from established C5 inhibitors (eculizumab, ravulizumab)"
      ],
      "potential_indications": "MMN, CIDP, MG combination, and other complement-mediated diseases"
    }
  },
  "mechanism": {
    "mechanism_of_action": "C2 sweeping antibody",
    "description": "Empasiprubart binds complement C2 and accelerates its degradation through a 'sweeping' mechanism, leading to sustained reduction in C2 levels and inhibition of classical/lectin complement pathway activation",
    "key_features": [
      "First-in-class C2 sweeping antibody",
      "Upstream complement inhibition",
      "Sustained C2 reduction",
      "Differentiated from C5 inhibitors"
    ]
  },
  "clinical_data": {
    "mmn_program": {
      "trial_name": "EMPASSION",
      "indication": "Multifocal Motor Neuropathy (MMN)",
      "phase": "Phase 3",
      "design": "Head-to-head trial vs IVIg",
      "readout": "4Q 2026",
      "de_risking": "Phase 2 EMPASSION proof-of-concept",
      "phase_2_results": {
        "endpoint": "Grip strength",
        "observation": "Sustained improved grip strength in MMN through ARDA Phase 2 and ARDA+ Open Label Extension",
        "durability": "Improvements maintained through 64+ weeks"
      }
    },
    "cidp_program": {
      "indication": "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",
      "phase": "Phase 2/3",
      "readout": "2H 2027",
      "strategy": "Co-positioning with VYVGART; multiple MOAs"
    },
    "mg_combination": {
      "trial_name": "ADAPT Forward",
      "description": "Efgartigimod + empasiprubart combination study",
      "rationale": "Combine FcRn inhibition (IgG reduction) with complement inhibition for enhanced efficacy",
      "status": "Exploring combination approaches"
    }
  },
  "market_opportunity": {
    "mmn": {
      "global_patients": "12,000 across key markets",
      "current_market": "$750-800M",
      "projected_market_2030": ">$1B",
      "unmet_need": {
        "misdiagnosis_rate": "40% initially misdiagnosed (often as ALS)",
        "targeted_treatments": "0 approved targeted treatments",
        "progression_despite_treatment": "60% progress despite IVIg treatment",
        "severe_disability": "20% of patients develop severe disability"
      },
      "disease_burden": "Progressive, often misdiagnosed as ALS; severe disability in 20%"
    },
    "cidp": {
      "us_diagnosed": "42,000 patients",
      "us_treated": "24,000 patients",
      "strategy": "Second MOA after VYVGART; potential for combination or sequential use"
    }
  },
  "competitive_landscape": {
    "complement_inhibitors": {
      "c5_inhibitors": {
        "eculizumab_soliris": "Approved for multiple indications (PNH, aHUS, gMG, NMOSD)",
        "ravulizumab_ultomiris": "Long-acting C5 inhibitor",
        "position": "Established downstream inhibitors"
      },
      "empasiprubart_differentiation": [
        "First-in-class C2 sweeping mechanism",
        "Upstream inhibition may provide broader/different efficacy",
        "Sustained C2 depletion vs intermittent C5 blockade",
        "Potentially different safety/efficacy profile"
      ]
    }
  },
  "investment_analysis": {
    "stage_value": "Phase 3 - high value inflection with MMN readout in 4Q 2026",
    "differentiation_strength": "Strong - first-in-class C2 sweeper",
    "competitive_position": "Novel mechanism vs established C5 inhibitors",
    "commercial_potential": {
      "mmn_alone": ">$1B market by 2030",
      "cidp_potential": "Second MOA in 42K patient market",
      "combination_potential": "Synergy with VYVGART in MG and other indications"
    },
    "key_risks": [
      "Phase 3 execution in MMN",
      "Head-to-head vs IVIg design",
      "Novel mechanism without approved precedent"
    ],
    "key_data_to_watch": [
      "MMN Phase 3 EMPASSION readout (4Q 2026)",
      "CIDP Phase 2/3 readout (2H 2027)",
      "ADAPT Forward combination data"
    ]
  },
  "catalysts": [
    {
      "event": "MMN Phase 3 EMPASSION readout",
      "timing": "4Q 2026",
      "significance": "First Phase 3 for empasiprubart; >$1B market opportunity"
    },
    {
      "event": "CIDP Phase 2/3 readout",
      "timing": "2H 2027",
      "significance": "Second molecule in CIDP; combination potential"
    }
  ]
}
